PharmaEssentia (8Z1) Stock Overview

A biopharmaceutical company engages in medicine discovery, supplements in developing specialty pharmaceutical reagents, API, and new drug patterns developments in the Americas, Europe, Asia, and Taiwan. More details

8Z1 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	6/6
Past Performance	4/6
Financial Health	6/6
Dividends	0/6

Rewards

Earnings are forecast to grow 50.27% per year

Earnings grew by 70.1% over the past year

Risk Analysis

Shares are highly illiquid

High level of non-cash earnings

8Z1 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

UNCYFeatured

Looking to be second time lucky with a game-changing new product

Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.

View narrative

stuart_roberts

Community Contributor

US$21.53FV • 64.4% undervalued

5419.8%Revenue growth p.a.

6.2k

126

3mo ago

PharmaEssentia Corporation Competitors

Price History & Performance

Summary of share price highs, lows and changes for PharmaEssentia
Historical stock prices
Current Share Price	NT$15.50
52 Week High	NT$15.50
52 Week Low	NT$15.50
Beta	0.42
1 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	0%

Recent updates

Shareholder Returns

	8Z1	DE Biotechs	DE Market
7D	0%	3.3%	-0.4%
1Y	n/a	-4.2%	3.0%

Return vs Industry: Insufficient data to determine how 8Z1 performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how 8Z1 performed against the German Market.

Price Volatility

Is 8Z1's price volatile compared to industry and market?
8Z1 volatility
8Z1 Average Weekly Movement	n/a
Biotechs Industry Average Movement	8.7%
Market Average Movement	6.0%
10% most volatile stocks in DE Market	12.4%
10% least volatile stocks in DE Market	2.6%

Stable Share Price: 8Z1's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine 8Z1's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1990	n/a	Ko-Chung Lin	www.pharmaessentia.com

PharmaEssentia Corporation, a biopharmaceutical company engages in medicine discovery, supplements in developing specialty pharmaceutical reagents, API, and new drug patterns developments in the Americas, Europe, Asia, and Taiwan. Its products include BESREMi, an interferon therapy indicated for polycythemia vera, essential thrombocythemia, PMF, and adult T-cell leukemias. The company also develops Ropeg + anti PD-1; PEG-IL-2 (P11838); PEG-Cytokines; PD-1-IL-2v; ADC; ADCS; NY-ESO-1 TCR-T; and Novel TCR-T for the treatment of solid tumor and immunology.

PharmaEssentia Corporation Fundamentals Summary

How do PharmaEssentia's earnings and revenue compare to its market cap?
8Z1 fundamental statistics
Market cap	€6.62b
Earnings (TTM)	€136.23m
Revenue (TTM)	€422.18m

48.8x

P/E Ratio

15.8x

P/S Ratio

Is 8Z1 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
8Z1 income statement (TTM)
Revenue	NT$15.63b
Cost of Revenue	NT$1.68b
Gross Profit	NT$13.95b
Other Expenses	NT$8.91b
Earnings	NT$5.05b

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	13.59
Gross Margin	89.23%
Net Profit Margin	32.27%
Debt/Equity Ratio	0.2%

How did 8Z1 perform over the long term?

See historical performance and comparison

Dividends

0.2%

Current Dividend Yield

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/04/30 15:42
End of Day Share Price	2026/03/09 00:00
Earnings	2025/12/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

PharmaEssentia Corporation is covered by 7 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Jianzheng Wu	Capital Securities Corporation
Wangbin Zhou	Citigroup Inc
Hsuan Chen	KGI Securities Co. Ltd.

PharmaEssentia CorporationDB:8Z1 Stock Report